JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

Autoimmune hepatitis and viral infection.

In summary, type 1 autoimmune hepatitis is infrequently associated with serologic markers of viral infection, and there is no direct evidence that viruses are important causes of this disease. Patients seropositive for anti-LKM1 are commonly infected with HCV, but these patients have predominant features of chronic viral hepatitis and frequently lack antibodies to P450IID6. Such patients respond to therapy with interferon and should be distinguished from patients with type 2 autoimmune hepatitis who have anti-P450IID6, seronegativity for anti-HCV, and responsiveness to corticosteroids. In patients with ANA and/or SMA seropositivity and anti-HCV, a false-positive reaction for anti-HCV must be excluded by recombinant immunoblot assay. Patients with false anti-HCV seropositivity should be treated with corticosteroids. In contrast, patients with a true viral infection and low-titer autoantibodies should be treated with interferon. In patients with true viral infection and high titers of auto-antibodies, the treatment decision must balance the autoimmune and viral manifestations. An empiric trial of corticosteroids is justified if autoimmune features predominate.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app